Synlogic stock.
Oct 3, 2023 · Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic ...
Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October ...View the latest Synlogic Inc. (SYBX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Get the latest Synlogic, Inc. (SYBX) stock news and headlines to help you in your trading and investing decisions.In discussing Synlogic (NASDAQ: SYBX) stock, let’s begin with the upside because it’s substantial. SYBX shares carry an average target price of $7.17 yet trade for $0.65.
24.65%. Get the latest Synlogic Inc (SYBX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
The last twelve months weren't great for Synlogic shares, which cost holders 12%, while the market was up about 15%. Of course the long term matters more than the short term, and even great stocks ...
Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...0A8U Stock Overview. Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Over the past week, Wood has been accumulating shares of Verve Therapeutics (VERV-6.12%) for her firm's flagship growth stock fund, the ARK Innovation ETF (ARKK 0.43%), and the biotech-focused ARK ...
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU). “We are …
Synlogic, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its ...
Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis.Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis. According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.To take any of these actions regarding your Synlogic stock, please contact the American Stock Transfer & Trust Company, LLC, Synlogic’s transfer agent. Some of these requests may involve a fee. American Stock Transfer & Trust Company (800) 937-5449 (Toll-free) (718) 921-8124 (International)٣١/٠١/٢٠١٨ ... Was this some sort of “pivot”? Turns out that it's actually a secondary offering, not an IPO, and it is now an entirely new company as a result ...Synlogic and Mirna Therapeutics Agree to Merger. May 16, 2017. PDF Version. – Transaction Expected to Advance Synlogic’s Innovative Platform for the Discovery and Development of Novel Synthetic Biotic™ Medicines –. – Synlogic Closes $42 Million of Series C Preferred Stock Financing by LeadingBiotechnology Investors –.Synlogic, Inc. CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S ...
CAMBRIDGE, Mass., March 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the fourth quarter and full year ended December 31, 2020, and provided an update on programs and progress.Synlogic has also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout.Nov 9, 2023 · Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November. Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting. March 20, 2023.Synlogic, Inc. Common Stock (SYBX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Business News - Latest Headlines on CNN Business - CNNNov 9, 2023 · Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options ...
You may vote if you were the record owner of Synlogic, Inc. common stock at the close of business on April 18, 2023 (the “Record Date”). A list of registered stockholders as of the close of business on the Record Date will be available at our corporate headquarters for examination by any stockholder for any purpose germane to the Annual Meeting for a …
Nov 22, 2023 · A high-level overview of Synlogic, Inc. (SYBX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Nov 24, 2023 · Chardan Raises Price Target on Synlogic to $6 From $5.50 Reflecting Lower Cash Burns Due to Recent Downsizing, Keeps Buy Rating. Jun. 06. MT. SVB Securities Cuts Synlogic's Price Target to $4 From $8, Maintains Outperform Rating. May. 12. MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept. About Synlogic. Synlogic ™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways.Discover historical prices for SYBX stock on Yahoo Finance. View daily, weekly or monthly format back to when Synlogic, Inc. stock was issued. Synlogic has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 3rd, 2024 based off last year's report dates. Learn more on SYBX's earnings history.Information on stock, financials, earnings, subsidiaries, investors, and executives for Synlogic. Use the PitchBook Platform to explore the full profile.Synlogic (NASDAQ:SYBX) is another biotech company, this time promising to treat diseases with high unmet need. It is a synthetic biology company focused on harnessing the power of artificial ...
Sep 21, 2023 · CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (Reverse Stock Split), effective at 5:00 p.m. Eastern Time on Wednesday ...
SYBX shares carry an average target price of $7.17 yet trade for $0.65. They are therefore a 10X opportunity based on Wall Street consensus. The company reported a small amount of revenue in the ...
Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement.Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...To take any of these actions regarding your Synlogic stock, please contact the American Stock Transfer & Trust Company, LLC, Synlogic’s transfer agent. Some of these requests may involve a fee. American Stock Transfer & Trust Company (800) 937-5449 (Toll-free) (718) 921-8124 (International) [email protected] is a biotechnology company that designs Synthetic Biotics, living probiotics that treat diseases with Synthetic Biotic pipeline. The web page provides stock quote, chart, news releases, events, and corporate documents of Synlogic, as well as investor resources and contact information.0A8U Stock Overview. Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States.Dec 1, 2023 · Earnings Flash (SYBX) SYNLOGIC Posts Q3 Revenue $393,000. Nov. 09. MT. Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 09. CI. Synlogic, Inc. Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration. Nov. 07. CI. Synlogic ( NASDAQ:SYBX ) First Quarter 2023 Results Key Financial Results Net loss: US$15.6m (flat on 1Q 2022). ... It does not constitute a recommendation to buy or sell any stock, ...Mar 29, 2023 · Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ... Find out all the key statistics for Synlogic, Inc. (SYBX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are ...Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.A. Synlogic ( SYBX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 9, 2023 for Q3 and the Actual Revenue was $393K, which beat ...Instagram:https://instagram. hacax holdingshow to become a day trader with dollar100spy price predictionpolestar nyse About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the first half of 2023, and additional novel drug candidates designed to treat ...Sep 27, 2023 · Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ... stocks dividend datescarrier global stock price Mar 24, 2021 · CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of SYNB8802. sprott etf CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ...Find out all the key statistics for Synlogic, Inc. (SYBX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.